Clinical, pathologic or molecular feature | Total N | LINE-1 methylation level | P value^ | |
---|---|---|---|---|
 |  | ≥40 | < 40 |  |
All cases | 869 | 847 | 22 | Â |
Sex | Â | Â | Â | 1.00 |
Men | 394 (45%) | 384 (45%) | 10 (45%) | Â |
Women | 475 (55%) | 463 (55%) | 12 (55%) | Â |
Age (years) | Â | Â | Â | 0.0058 |
< 60 | 196 (23%) | 186 (22%) | 10 (45%) | Â |
60-69 | 363 (42%) | 360 (43%) | 3 (14%) | Â |
≥70 | 310 (36%) | 301 (36%) | 9 (41%) |  |
Body mass index (BMI, kg/m2) | Â | Â | Â | 1.00 |
< 30 | 667 (83%) | 649 (82%) | 18 (86%) | Â |
≥30 | 141 (17%) | 138 (18%) | 3 (14%) |  |
Family history of colorectal cancer | Â | Â | Â | 0.80 |
(-) | 657 (76%) | 641 (76%) | 16 (73%) | Â |
(+) | 212 (24%) | 206 (24%) | 6 (27%) | Â |
Smoking status | Â | Â | Â | 0.082 |
Never | 349 (41%) | 336 (40%) | 13 (59%) | Â |
Past or current | 508 (59%) | 499 (60%) | 9 (41%) | Â |
Tumor location | Â | Â | Â | 0.094 |
Proximal colon (cecum to transverse) | 370 (44%) | 365 (45%) | 5 (25%) | Â |
Distal colon (splenic flexure to sigmoid) | 274 (33%) | 263 (32%) | 11 (55%) | Â |
Rectum | 192 (23%) | 188 (23%) | 4 (20%) | Â |
Disease stage | Â | Â | Â | 0.66 |
I | 196 (25%) | 193 (25%) | 3 (14%) | Â |
II | 253 (33%) | 246 (32%) | 7 (33%) | Â |
III | 226 (29%) | 218 (29%) | 8 (38%) | Â |
IV | 103 (13%) | 100 (13%) | 3 (14%) | Â |
Tumor grade | Â | Â | Â | 0.45 |
Low | 777 (91%) | 758 (91%) | 19 (86%) | Â |
High | 79 (9.2%) | 76 (9.1%) | 3 (14%) | Â |
Mucinous component | Â | Â | Â | 0.53 |
0% | 554 (65%) | 541 (65%) | 13 (59%) | Â |
1-49% | 188 (22%) | 181 (22%) | 7 (32%) | Â |
≥50% | 115 (13%) | 113 (14%) | 2 (9.1%) |  |
Signet ring cell component | Â | Â | Â | 1.00 |
0% | 796 (93%) | 775 (93%) | 21 (95%) | Â |
1-49% | 48 (5.6%) | 47 (5.6%) | 1 (4.5%) | Â |
≥50% | 14 (1.6%) | 14 (1.7%) | 0 |  |
Crohn's-like reaction | Â | Â | Â | 1.00 |
Absent/mild | 584 (90%) | 571 (90%) | 13 (93%) | Â |
Moderate/severe | 62 (9.6%) | 61 (9.7%) | 1 (7.1%) | Â |
Peritumoral lymphocytic reaction | Â | Â | Â | 0.73 |
Absent/mild | 744 (89%) | 725 (89%) | 19 (86%) | Â |
Moderate/severe | 93 (11%) | 90 (11%) | 3 (14%) | Â |
Tumor infiltrating lymphocytes (TIL) | Â | Â | Â | 0.73 |
Absent/mild | 740 (89%) | 721 (89%) | 19 (86%) | Â |
Moderate/severe | 96 (11%) | 93 (11%) | 3 (14%) | Â |
MSI status | Â | Â | Â | 0.76 |
MSI-low/MSS | 728 (85%) | 709 (85%) | 19 (90%) | Â |
MSI-high | 124 (15%) | 122 (15%) | 2 (9.5%) | Â |
CIMP status | Â | Â | Â | 0.14 |
CIMP-0 | 408 (47%) | 393 (46%) | 15 (68%) | Â |
CIMP-low | 333 (38%) | 327 (39%) | 6 (27%) | Â |
CIMP-high | 128 (15%) | 127 (15%) | 1 (4.6%) | Â |
KRAS mutation | Â | Â | Â | 0.38 |
(-) | 538 (63%) | 522 (63%) | 16 (73%) | Â |
(+) | 319 (37%) | 313 (37%) | 6 (27%) | Â |
BRAF mutation | Â | Â | Â | 1.00 |
(-) | 728 (87%) | 709 (87%) | 19 (90%) | Â |
(+) | 108 (13%) | 106 (13%) | 2 (9.5%) | Â |
PIK3CA mutation | Â | Â | Â | 0.76 |
(-) | 646 (85%) | 627 (84%) | 19 (90%) | Â |
(+) | 118 (15%) | 116 (16%) | 2 (9.5%) | Â |
TP53 expression | Â | Â | Â | 0.19 |
(-) | 488 (57%) | 472 (56%) | 16 (73%) | Â |
(+) | 371 (43%) | 365 (44%) | 6 (27%) | Â |
CDKN1A | Â | Â | Â | 0.099 |
Lost | 682 (81%) | 661 (81%) | 21 (95%) | Â |
Expressed | 158 (19%) | 157 (19%) | 1 (4.6%) | Â |
CTNNB1 score* | Â | Â | Â | 1.00 |
0-2 (inactive) | 482 (64%) | 470 (64%) | 12 (63%) | Â |
3-5 (active) | 273 (36%) | 266 (36%) | 7 (37%) | Â |
PTGS2 expression | Â | Â | Â | 0.073 |
(-) | 142 (16%) | 135 (16%) | 7 (32%) | Â |
(+) | 719 (84%) | 704 (84%) | 15 (68%) | Â |
FASN expression | Â | Â | Â | 0.50 |
(-) | 742 (88%) | 721 (88%) | 21 (95%) | Â |
(+) | 99 (12%) | 98 (12%) | 1 (4.6%) | Â |